{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:42:29Z","timestamp":1772822549165,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.blre.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T17:56:32Z","timestamp":1439920592000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?"],"prefix":"10.1016","volume":"30","author":[{"given":"Javeed","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Naushad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayla B.","family":"Heavican","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Bouska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.blre.2015.08.003_bb0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2015.08.003_bb0015","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/t-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.08.003_bb0020","series-title":"WHO classification: pathology and genetics of tumors of haematopoietic and lymphoid tissues","volume":"4","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.blre.2015.08.003_bb0025","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2796.1998.00343.x","article-title":"The genetic analysis of cancer","volume":"243","author":"Pearson","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2015.08.003_bb0035","first-page":"829","article-title":"Fundamentals of DNA-chip\/array technology for comparative gene-expression analysis","volume":"83","author":"Saluz","year":"2002","journal-title":"Curr Sci"},{"issue":"10","key":"10.1016\/j.blre.2015.08.003_bb0040","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"6769","key":"10.1016\/j.blre.2015.08.003_bb0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.blre.2015.08.003_bb0050","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0055","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2015.08.003_bb0060","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.blre.2015.08.003_bb0070","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2015.08.003_bb0075","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0080","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2015.08.003_bb0085","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2015.08.003_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.781","article-title":"Peripheral T-cell lymphoma gene expression profiles","volume":"24","author":"Martinez-Delgado","year":"2006","journal-title":"Hematol Oncol"},{"issue":"22","key":"10.1016\/j.blre.2015.08.003_bb0095","doi-asserted-by":"crossref","first-page":"10,703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation","volume":"67","author":"Piccaluga","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2015.08.003_bb0100","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.blre.2015.08.003_bb0105","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"25","author":"Ballester","year":"2006","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.blre.2015.08.003_bb0110","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Cuadros","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0115","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Martinez-Delgado","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2002-05-1352","article-title":"Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL","volume":"103","author":"Tsuchiya","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2015.08.003_bb0125","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/leu.2010.255","article-title":"Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro","volume":"25","author":"Iqbal","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.blre.2015.08.003_bb0140","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2015.08.003_bb0145","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0150","series-title":"Paper presented at: 56th ASH Annual Meeting and Exposition","article-title":"803 Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-\u03b4,\u03b3 Inhibitor, Shows Activity in Patients with Relapsed\/Refractory T-Cell Lymphoma","author":"Horwitz","year":"2014"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0155","first-page":"140","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"Rudiger","year":"2002","journal-title":"ESMO"},{"issue":"25","key":"10.1016\/j.blre.2015.08.003_bb0160","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","article-title":"The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Armitage","year":"2012","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"de Leval","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2015.08.003_bb0180","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2015.08.003_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092585","article-title":"No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.blre.2015.08.003_bb0190","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2015.08.003_bb0195","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"5196","key":"10.1016\/j.blre.2015.08.003_bb0200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.267.5196.316-b","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"267","author":"Morris","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.1990.tb02560.x","article-title":"CD30-positive large cell lymphomas (\u2018Ki-1 lymphoma\u2019) are associated with a chromosomal translocation involving 5q35","volume":"74","author":"Mason","year":"1990","journal-title":"Br J Haematol"},{"issue":"5151","key":"10.1016\/j.blre.2015.08.003_bb0210","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2141.1989.tb06270.x","article-title":"A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (\u2018Ki-1 lymphoma\u2019)","volume":"71","author":"Rimokh","year":"1989","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0220","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1172\/JCI29401","article-title":"Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes","volume":"116","author":"Piva","year":"2006","journal-title":"J Clin Invest"},{"issue":"26","key":"10.1016\/j.blre.2015.08.003_bb0225","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1182\/blood-2011-05-354654","article-title":"miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma","volume":"118","author":"Matsuyama","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0230","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2012-01-405555","article-title":"Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma","volume":"120","author":"Agnelli","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0235","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/leu.2014.347","article-title":"A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation","volume":"29","author":"Abate","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2015.08.003_bb0240","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2015.08.003_bb0245","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"issue":"39","key":"10.1016\/j.blre.2015.08.003_bb0250","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/sj.onc.1208968","article-title":"Global epidemiology of HTLV-I infection and associated diseases","volume":"24","author":"Proietti","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2015.08.003_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-230X(03)01003-0","article-title":"Seizing of T cells by human T-cell leukemia\/lymphoma virus type 1","volume":"89","author":"Franchini","year":"2003","journal-title":"Adv Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2015.08.003_bb0260","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2004-03-1222","article-title":"Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia","volume":"105","author":"Sasaki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0265","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2008-08-175901","article-title":"Gene expression profiling of ATL patients: compilation of disease related genes and evidence for TCF-4 involvement in BIRC5 gene expression and cell viability","volume":"113","author":"Pise-Masison","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0270","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal-type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0275","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat Commun"},{"issue":"50","key":"10.1016\/j.blre.2015.08.003_bb0280","doi-asserted-by":"crossref","first-page":"20,119","DOI":"10.1073\/pnas.1115128108","article-title":"PRDM1 is a tumor suppressor gene in natural killer cell malignancies","volume":"108","author":"Kucuk","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0285","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2009.3","article-title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies","volume":"23","author":"Iqbal","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajpath.2012.09.012","article-title":"HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms","volume":"182","author":"Kucuk","year":"2013","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.blre.2015.08.003_bb0295","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0305","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2008-07-166363","article-title":"Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma","volume":"113","author":"Miyazaki","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0310","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"7074","key":"10.1016\/j.blre.2015.08.003_bb0315","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0320","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0325","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2015.08.003_bb0330","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2462.2462","article-title":"Phase II study of proteasome inhibitor bortezomib (Velcade\u00ae) in patients with relapsed\/refractory T-cell lymphoma: preliminary results","volume":"108","author":"Zinzani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0340","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18,770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0345","first-page":"3351a","article-title":"Preliminary results of a phase II study of Lenalidomide in patients with cutaneous T-cell lymphom","volume":"106","author":"Querfeld","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.08.003_bb0350","doi-asserted-by":"crossref","first-page":"690a","DOI":"10.1182\/blood.V110.11.690.690","article-title":"Syk tyrosine kinase is overexpressed in the majority of peripheral T and NK-cell lymphomas, and Re","volume":"110","author":"Feldman","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","article-title":"Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines","volume":"24","author":"Wilcox","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0360","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(05)70213-8","article-title":"Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified","volume":"6","author":"Piccaluga","year":"2005","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.blre.2015.08.003_bb0365","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2015.08.003_bb0370","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/leu.2014.50","article-title":"Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway","volume":"28","author":"Piccaluga","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2015.08.003_bb0375","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0385","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2015.08.003_bb0390","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0395","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/1521-4141(2000012)30:12<3403::AID-IMMU3403>3.0.CO;2-H","article-title":"Rho regulates T cell receptor ITAM-induced lymphocyte spreading in an integrin-independent manner","volume":"30","author":"Borroto","year":"2000","journal-title":"Eur J Immunol"},{"issue":"1\u20132","key":"10.1016\/j.blre.2015.08.003_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2011.12.003","article-title":"Rho GTPases: masters of T lymphocyte migration and activation","volume":"142","author":"Rougerie","year":"2012","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.onc.1203259","article-title":"Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma","volume":"19","author":"Cleverley","year":"2000","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.blre.2015.08.003_bb0410","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2015.08.003_bb0420","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0425","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3324\/haematol.2013.088740","article-title":"Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma","volume":"98","author":"Asmar","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2015.08.003_bb0430","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.stem.2011.07.010","article-title":"Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development","volume":"9","author":"Dawlaty","year":"2011","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0440","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.blre.2015.08.003_bb0445","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0450","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.13170","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma","volume":"168","author":"Cheminant","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2015.08.003_bb0455","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas","volume":"28","author":"Nicolae","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2015.08.003_bb0460","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2015.08.003_bb0465","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.08.003_bb0470","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2006.1.331","article-title":"Therapy of peripheral T\/NK neoplasms","author":"Greer","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2015.08.003_bb0475","article-title":"High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) as first line treatment in peripheral T-cell lymphoma (PTCL)","author":"d' Amore","year":"2005","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.blre.2015.08.003_bb0480","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2015.08.003_bb0485","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.blre.2015.08.003_bb0490","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2015.08.003_bb0495","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/PPO.0b013e31803c73cc","article-title":"Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy","volume":"13","author":"Piekarz","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2015.08.003_bb0505","article-title":"PDX produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I\/II experience","volume":"108","author":"O'Connor","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2015.08.003_bb0510","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V122.21.368.368","article-title":"High response rates to Crizotinib in advanced, chemoresistant ALK+ lymphoma patients","volume":"122","author":"Redaelli","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2015.08.003_bb0515","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.blre.2015.08.003_bb0520","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2015.08.003_bb0525","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2015.08.003_bb0530","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2015.08.003_bb0535","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.blre.2015.08.003_bb0540","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.08.003_bb0545","doi-asserted-by":"crossref","first-page":"s850","DOI":"10.1200\/jco.2013.31.15_suppl.8507","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): Results from the BELIEF trial [abstract]","volume":"31","author":"O'Connor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2015.08.003_bb0550","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2015.08.003_bb0555","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2015.08.003_bb0560","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T09:03:05Z","timestamp":1599469385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X15000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0268960X15000648"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2015.08.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}